Table 1.
Patient characteristics
| n | % | ||
|---|---|---|---|
| Age | Median | 64 | |
| Range | 41–83 | ||
| Gender | Male | 21 | 44 |
| Female | 27 | 56 | |
| Performance status | 0 | 29 | 60 |
| 1 | 17 | 35 | |
| 2 | 2 | 4 | |
| Pancreatic tumor location | Head | 22 | 46 |
| Body/Tail | 26 | 54 | |
| Metastatic site | Local invasion | 8 | 17 |
| Liver | 16 | 33 | |
| Lung | 9 | 19 | |
| Peritoneal | 5 | 10 | |
| Multiple | 10 | 21 | |
| CA19-9 (U/ml) | Median | 499.8 | |
| Range | 0.5–20379.8 | ||
| CEA (ng/ml) | Median | 7 | |
| Range | 2.0–281.4 | ||
| Previous therapy | Chemotherapy | 21 | 44 |
| Surgery | 11 | 23 | |
| Radiation | 3 | 6 | |
| None | 13 | 27 | |
| Concurrent chemotherapy | GnP | 33 | 69 |
| FOLFIRINOX | 15 | 31 | |
| Postvaccination chemotherapy | S-1 | 10 | 16 |
| GEM | 6 | 10 | |
| GEM+S-1 | 3 | 4 | |
| GnP | 25 | 41 | |
| FOLFIRINOX | 12 | 20 | |
| BSC | 5 | 8 |
Abbreviations: CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; S-1, tegafur gimeracil oteracil; GEM, gemcitabine; GnP, GEM+nab-paclitaxel; FOLFIRINOX, oxaliplatin, irinotecan, fluorouracil, and leucovorin; BSC, best supportive care.